Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock
PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or…
News
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
TUSTIN, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated…
Transactions in connection with share buyback program
Company announcement no. 49 – 201 December 2020 Transactions in connection with share buyback program…
Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
Mechelen, Belgium; 1 December 2020, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces first…
Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)
Planned enrollment of the first patient in the OLYMPIA Phase 2 study in 1H 2021…
Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue
CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) — Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”),…
FDA approves Xolair® (omalizumab) for adults with nasal polyps
Xolair is the first biologic for the treatment of nasal polyps that targets and blocks…
Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq
East Setauket, NY, Dec. 01, 2020 (GLOBE NEWSWIRE) — Lixte Biotechnology Holdings, Inc. (“Lixte” or…
Rafarma Inks Joint Venture Agreement with Vaccines Lab SDN BHD of Malaysia
Nicosia, Cyprus, Dec. 01, 2020 (GLOBE NEWSWIRE) — Rafarma Pharmaceuticals, Inc. OTC:(RAFA) has signed a…
Sun BioPharma, Inc. Changes Name to Panbela Therapeutics Inc.
MINNEAPOLIS, Dec. 01, 2020 (GLOBE NEWSWIRE) — Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage…